Jimmy Wales-backed mobile network The People’s Operator celebrates better than expected six months

first_imgCommercial mobile phone network The People’s Operator (TPO) saw subscriber numbers grow by 140 per cent in the second half of last year, to 14,032 from 5,800.The final two months of 2014 saw the number of subscribers for the cause-based mobile operator, which is led by Wikipedia founder Jimmy Wales, go up by 28 per cent, from 10,913 at 31 October.The company said in a trading update yesterday that the increase in customers significantly exceeded its initial expectations for the year and reported that monthly subscriber revenues from pay monthly customers went up by 141 per cent in the six months to 31 December. In addition, the firm reported that average revenues per subscriber and average customer acquisitions costs remain in line with those set out in its Aim admission document.The group also stated that it remains on track with its US launch, having signed a deal with US network operator Sprint last year, and the development of its new social network platform, which is set to launch this year. Wales has also spent time “exploring the market” in the Middle East and the company said yesterday that it may expand into Mexico, Brazil and Asia.Mark Epstein, chief executive of TPO, commented: “We are pleased to have achieved strong growth in our subscriber numbers and to have finished the year substantially ahead of our targets. This performance gives us confidence for 2015, as we launch our new online, cause based community platform and expand into the US.”TPO raised £20m ahead of floating on Aim in December 2014 in a move that attracted interest from institutional investors such as Aviva, JP Morgan and Allianz. Executive director of strategy and digital community Wales said at the time that TPO has decided to list “because we wanted to have the transparency that being a public company provides.”Shares in the company went up by 1.8 per cent yesterday. whatsapp Share Show Comments ▼ Jimmy Wales-backed mobile network The People’s Operator celebrates better than expected six months center_img whatsapp Express KCS Tags: NULL Monday 12 January 2015 8:22 pmlast_img read more

Read More →

General Election 2015: Labour might have a four-point lead in the polls but Conservatives are favourites to win at the bookies, with odds of 1/2 to get the most seats

first_img by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeMoneyPailShe Was A Star, Now She Works In ScottsdaleMoneyPailzenherald.comMeghan Markle Changed This Major Detail On Archies Birth Certificatezenherald.comMaternity WeekA Letter From The Devil Written By A Possessed Nun In 1676 Has Been TranslatedMaternity WeekComedyAbandoned Submarines Floating Around the WorldComedyForbesThese 10 Colleges Have Produced The Most Billionaire AlumniForbesGameday NewsNBA Wife Turns Heads Wherever She GoesGameday NewsEquity MirrorThey Drained Niagara Falls — They Weren’t Prepared For This Sickening DiscoveryEquity MirrorNoteableyKirstie Alley Is So Skinny Now And Looks Like A BarbieNoteableyBridesBlushThis Is Why The Royal Family Kept Quiet About Prince Harry’s Sister BridesBlush More From Our Partners Police Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgI blew off Adam Sandler 22 years ago — and it’s my biggest regretnypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comKiller drone ‘hunted down a human target’ without being told tonypost.com whatsapp General Election 2015: Labour might have a four-point lead in the polls but Conservatives are favourites to win at the bookies, with odds of 1/2 to get the most seats Tags: Company General Election 2015 Ladbrokes Show Comments ▼ Sharecenter_img Monday 30 March 2015 10:02 am Labour may have made a surprise gain of four points in the polls over the weekend, but the Conservatives are firm favourites to get the most seats at the bookies, Ladbrokes said today, with odds of 1/2 as the campaigns kick off. Meanwhile, Labour’s odds have shortened in the last 24 hours, from 7/4 to 13/8. Ukip gets just 100/1 – although both the Lib Dems and the Green party suffer the indignity of odds of 500/1.  If the bookies are right, it looks set to be another hung parliament: the odds of no overall majority are at a paltry 1/5. The odds also favour a Labour minority government, at 2/1, with a Conservative equivalent at 5/2.No wonder they say the outcome of this election is the most difficult to predict in a generation – although that, presumably, is also the reason gamblers are expected to punt £100m on the election. In fact, added Ladbrokes, the election is about to become the biggest non-sporting events in history. That figure is twice the £50m fluttered on the Scottish referendum, and more than three times the £30m bet on the General Election in 2010. Just don’t forget to vote… Emma Haslett whatsapplast_img read more

Read More →

Episode 4: A shoppers guide to the genome sequencing market

first_img About the Authors Reprints Molly Ferguson for STAT By Meg Tirrell and Luke Timmerman Dec. 17, 2015 Reprints Meg Tirrell It’s the holidays! Looking for a gift that really shows you care? How about getting your loved one’s genome sequenced?It took 15 years and $3 billion to sequence the first human genome. But in the decade since then, that cost has come down dramatically. For a few years DNA sequencing was progressing faster than Moore’s law. Today you can get some genetic information for as little as $199.But the promise of genome sequencing has yet to be fulfilled. While companies like 23andme offer an affordable look at your genetic traits, a full genome scan will still run you a couple thousand dollars. And the FDA is still struggling with figuring out how to regulate these consumer genetic tests. But while the public appetite for these services may be small, companies like Illumina and Arivale are placing a bet on the wider applications of genome sequencing.advertisement Music:Rollin at 5 – 210 – full, by Kevin MacLeod Co-host “The Readout LOUD,” CNBC senior health and science reporter @megtirrell Tags geneticsgenome sequencing Signal PodcastEpisode 4: A shoppers guide to the genome sequencing market Is genome sequencing right for you? No matter what you spend on your personal genome, whether it’s $199 or $25,000, you’re still going to get back results you may not exactly be able to use in everyday life. But if your New Year’s resolution is to “know thyself” better, then this episode of Signal is for you.Subscribe to Signal on iTunes or Stitcher.The Signal podcast is produced by Katie Hiler.advertisementlast_img read more

Read More →

The dream of 3-D-printed organs rests on keeping cells alive. A new advance could help

first_img“They’re showing very elegantly in this work that we don’t need to over-engineer the system,” said Jordan Miller, a bioengineer at Rice University who was not involved in the study. The researchers got “functional tissue to emerge out of this provisional tissue they fabricated and implanted, which is just tremendously exciting.”The Wake Forest team’s 3-D printer at work fabricating a jaw bone structure. Wake Forest Institute for Regenerative MedicineThe Wake Forest team is one of many in mostly academic labs around the globe using molds to create a vascular system for 3-D-printed tissue.Other researchers have demonstrated vascularization techniques like seeding channels with the cells that line the inside of blood vessels, or connecting implants directly in line with a rat’s artery. Atala and his Wake Forest colleagues tried a different tack: relying on the host animal’s healing systems to naturally fill the empty channels with blood vessels.Figuring out how to pattern the rivers of microchannels is key to getting blood to flow properly between the layers of 3-D-printed cells because, without a blood supply, the dense layers of tissue found in complex organs won’t survive in any configuration that’s larger than about the thickness of a sheet of paper. That’s been “the basic limitation of this field forever up to this point,” Atala said.By contrast, 3-D printing is increasingly being used in the clinic for things like customized knee and jaw replacements using plastics and titanium. Those medical and dental applications represented a more than $500 million global market in 2014, according to Wohlers Associates, a Colorado-based consulting firm focused on 3-D-printing.But actually making something with living cells is a lot more challenging — and that’s slowed commercial development in the field significantly.“Getting investors on board for a long-term experimental study that may not pan out … is a difficult proposition for venture capitalists right now,” Miller said.Still, a few companies are still trying.A Texas startup called TeVido BioDevices is looking to 3-D-print skin and fat cells to create nipple grafts for breast cancer survivors undergoing reconstructive surgery. That’s much simpler than trying to print something like muscle, and it’s allowed them to produce tissue at larger sizes than if they’d needed blood channels to keep cells alive.But funding has been tough. Since its founding in 2011, the company has received only about $1.25 million, mostly from the US government’s Small Business Innovation Research program.“That’s one of the things that’s limiting our progress, obviously,” said Scott Collins, the company’s president. But he’s optimistic about TeVido’s bet on simpler tissues until the technical capabilities for more complex tissues catches up.Organovo, the world’s first publicly traded 3-D bioprinting company, is working with scientists at Yale University to solve some of these technical challenges to bioprinting human organs. But in the meantime, the San Diego firm is focused on selling 3-D-printed tissues for screening the toxicity of experimental drugs in the lab. “We’re trying to displace animal models,” said CEO Keith Murphy.The company started by offering human liver tissue for drug testing in late 2014. Kidney models will be rolled out later this year. Organs suitable for surgical transplantation will take a decade or more.The Wake Forest group’s next step is to do more testing in animals to assess whether their 3-D-printed tissue can survive and stay safe long-term. But Atala said it’s too early to talk about commercializing his team’s advance.Companies “are just treading the water right now in terms of looking at these systems and seeing how well they work,” he said.Elie Dolgin contributed reporting. In the LabThe dream of 3-D-printed organs rests on keeping cells alive. A new advance could help There’s plenty of excitement around the promise of machines that can spit out living cells patterned to create three-dimensional biological structures.But the dream of functional 3-D-printed tissue and organs has long been stymied by a stubborn central challenge: how to get blood to flow to keep the cells alive.Now, a team of researchers at the Wake Forest School of Medicine in North Carolina has made the latest contribution to solving the puzzle, though their findings are still a long way away from helping patients.advertisement By Rebecca Robbins Feb. 15, 2016 Reprints Tags medical devicesmedical technologyorgan transplant This 3-D-printed human cartilage possessed all the natural characteristics of an ear when implanted in a rodent model. Wake Forest Institute for Regenerative Medicine The researchers devised a printing method that allowed them to fabricate bone, muscle, and cartilage tissues threaded with tiny channels where blood vessels developed when implanted in mice and rats. Most strikingly, this method worked with cartilage tissue the size and shape of a human baby’s ear, a structure much larger than would have been possible to sustain without blood flow.“You’re basically creating a vascular network with a printer,” said Dr. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine. He and his colleagues reported the findings Monday in Nature Biotechnology.advertisementlast_img read more

Read More →

Meet the biotech company trying to shake up how the FDA thinks about cancer drugs

first_imgBiotech Meet the biotech company trying to shake up how the FDA thinks about cancer drugs What is it? About the Author Reprints Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Log In | Learn More @damiangarde Tags biotechnologycancerprecision medicineSTAT+ By Damian Garde June 3, 2017 Reprintscenter_img What’s included? Prostate cancer cells. NIH GET STARTED National Biotech Reporter Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast. Connecticut biotech Loxo Oncology is hoping to upend decades of Food and Drug Administration dogma with its cancer drug, seeking what would be a pioneering approval to treat a wide array of tumors with one pill. And, judging from an early peek at Loxo’s clinical data, experts say the plan just might work.Loxo’s drug, larotrectinib, is designed to kill off tumors by attacking a protein called TRK, which becomes hyperactive in people with certain genetic mutations. But where most drugs are studied in one cancer type at a time, Loxo aims to market its therapy for any tumor that expresses the TRK protein, and it’s building up evidence to convince the FDA. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. [email protected] Damian Gardelast_img read more

Read More →

As CRISPR patent fight nears the endgame, where are settlement talks?

first_img By Sharon Begley May 2, 2018 Reprints About the Author Reprints CRISPR pioneers Jennifer Doudna (left) of UC Berkeley and Feng Zhang (right) of the Broad Institute and MIT appeared together with journalist Michael Specter at a New Yorker magazine event in 2015. Anna Webber/Getty Images for The New Yorker Log In | Learn More What is it? Senior Writer, Science and Discovery (1956-2021) Sharon covered science and discovery. Sharon Begley Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.center_img As CRISPR patent fight nears the endgame, where are settlement talks? What’s included? [email protected] Business Three years after the University of California and the Broad Institute began battling over key patents on CRISPR-Cas9 genome editing inventions, the fat lady is finally about to sing in this multimillion-dollar operatic battle.The U.S. Court of Appeals for the Federal Circuit, which heard oral arguments in the case on Monday, is expected to rule within 90 days on whether the Broad can keep its foundational CRISPR patents, as the patent office ruled last year. (IP experts think the chances of the Supreme Court accepting the case, if the losing party tries that route, are comparable to those of the Baltimore Orioles winning the 2018 World Series.) Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. @sxbegle Tags biotechnologyCRISPRgeneticslegalSTAT+last_img read more

Read More →

Carney offers Canada parting advice on economy

Canadian trade deficit grew in October Ross Marowits Rejecting suggestions of being a “rock star central banker,” Carney credited a team of people that made crucial decisions. “I really don’t think you should judge your own legacy,” he said, adding it will take time for a full evaluation to emerge. Carney described his tenure during the financial crisis as being “very intense for a very long period of time.” “I think by and large the right decisions were made.” The central banker said Canada can seize opportunities to build a better future more than other countries because it doesn’t have to repair the economy or worry about getting out of trouble. But, he said, Canada is less well-oriented to the sources of global growth than it has been in the past. It must focus more carefully on exports and business investment, Carney said. He calculated that exports are currently $130 billion less than would have been the case in a typical postwar recession. That represents about eight per cent of gross domestic product. Carney said the Canadian government is correct in seeking out new trade deals, particularly in emerging economies, because they represent one half of the world’s imports growth and also are essential to securing a position in global supply chains. “To find and compete in new markets will require a concerted, multi-year effort by workers, firms and governments.” Carney has long stressed the need to transition Canada’s exports-based industries from reliance on slow-growing economies like the U.S. and Europe to fast-growing markets in China and Asia in general. But the advice took on added currency as it was likely the last time he will pronounce generally on the Canadian economy for at least the next five years, the term of his posting in London. Canada coped relatively well to the financial crisis, he said, noting that by the start of 2011 the country had recovered to the GDP level it held prior to the recession and that as of now, there are 480,000 more Canadians working than in the fall of 2008, when the slump began. It has been able to make the adjustments because fundamentally the Canadian system works, Carney said. Despite criticism, Canada’s labour market is relatively flexible, with labour mobility similar to that in the United States and about four times as flexible as in Europe. “Canadians are going where the jobs are,” he said. “Last year, there was a net inflow of more than 40,000 people into Alberta from the rest of Canada, a level of mobility that approaches its previous peak.” Carney said Canada also has a functioning monetary union despite the lament about provincial trade barriers and the two-speed economy caused by high commodity prices. He also praised what he calls “fiscal federalism,” the often maligned system of wealth transfers from have to have-not regions. Rather than a weakness, the system helps stabilize localized “asymmetric shocks” and share the risks, he said. Lastly, the central banker said Canada has been well-served by a sound and regulated banking sector, as well as low government debt that allowed policy-makers room to borrow on global markets to stimulate the economy. Carney said Canada cannot rest on its laurels, however. “In a rapidly shifting world, only sustained education, ingenuity and investment can maintain competitiveness,” he said. “This means we must continuously invest in our workforce. With technology and trade transforming the workplace, the need to improve skills across the spectrum of work has never been greater.” With files from Julian Beltrame in Ottawa Purchase of three icebreakers turns Canada’s August trade surplus into a deficit Canada has work to do, but it is stronger than when he took over as head of the Bank of Canada five years ago, outgoing governor Mark Carney said Tuesday. “We’re in a stronger relative position compared to other advanced economies today than we were in 2008 but we’re in a tougher world,” he said after making his final speech as governor before departing for the Bank of England next month. Higher oil prices helped narrow Canada’s trade deficit to $4.2B in January Share this article and your comments with peers on social media Related news Keywords ExportsCompanies Bank of Canada Facebook LinkedIn Twitter read more

Read More →

UK CMA proposes pension investment reforms

first_imgJames Langton Related news The UK Competition and Markets Authority (CMA) on Wednesday proposed a number of reforms to the investment consultancy and fiduciary management sector that advises pensions funds on investing after identifying a range of competition concerns.The CMA launched its market investigation in September 2017. It’s provisional findings include: Share this article and your comments with peers on social media FCA proposals aim to improve competition in the investment platform market about half of pension funds use the same firm for investment advice and fiduciary management;only a third of pension funds require firms to compete for their business, meaning that there is little competitive pressure on fees and performance; andpension funds often don’t have enough information to judge whether their fees are fair, or to assess the quality of service they are receiving.In response, the CMA recommends a number of reforms, including requiring pension funds to run competitive tenders for these services, enhancing fee and and performance disclosure, and developing new guidance for pension funds to oversee these providers. It also recommends that the UK Financial Conduct Authority (FCA) be given greater oversight of the sector.“We’re concerned that pension schemes are not currently putting pressure on the market to get the best value for money on behalf of their members. They may lack the information they need to compare competing offers and so could be sticking with their existing investment consultant or fiduciary manager when there are better options available,” says John Wotton, chairman of the CMA’s Investment Consultants Market Investigation, in a statement.“This is an extremely important sector that influences how well millions of people’s pension savings are invested, and it’s therefore vital we take steps to make sure that competition is working properly. That’s why we’re proposing a number of important reforms to the sector, including requiring pension trustees to run a competitive tender when they choose a fiduciary manager and ensuring that trustees have much better information about fees and investment performance,” he adds.In a statement on the report, the FCA says, “The CMA’s provisional findings about pension schemes trustees’ limited ability to drive competition between investment consultants and fiduciary managers are significant. These services matter because the firms involved provide advice and services to the pension schemes which so many consumers rely on.”“We look forward to reviewing the CMA’s detailed findings and suggested remedies, including their recommendation to extend the FCA’s regulatory perimeter, and will continue to work closely with the CMA in the coming months as the remedies are finalized,” the FCA adds.Comments on the proposals are due by Aug. 24. A final report from the CMA is due by March 13, 2019.center_img FCA introduces premium listing category for sovereign-controlled companies Keywords United KingdomCompanies Financial Conduct Authority Facebook LinkedIn Twitter FCA consults on duty of care requirementlast_img read more

Read More →

North American stocks bounce back from deep declines

first_img Ross Marowits upclose stock market arrows green and red piren/123RF S&P/TSX composite hits highest close since March on strength of financials sector “Not only is today a good example of that when we’ve seen some steep losses midday get reversed … but I think we’ve seen that show up over the past two weeks as well where two weeks ago we posted very strong gains in equities and last week gave them all back.”The S&P/TSX composite index closed down 66.85 points to 14,728.28 after hitting a triple-digit decline to a low of 14,610.18 in earlier trading.The consumer discretionary and energy sectors led on the downside as oil prices fell again despite last week’s decision by OPEC and Russia to cut production by 1.2 million barrels per day. The technology sector gained 1.6 %.The January crude contract was down US$1.61 at US$51 per barrel and the January natural gas contract was up US5.7¢ at US$4.54 per mmBTU.The Canadian dollar traded at an average of US74.62¢ compared with an average of US75.19¢ on Friday.The February gold contract was down US$3.20 at US$1,249.40 an ounce and the March copper contract was down US3.95¢ at US$2.72 a pound.Fehr said the market was hit early Monday with uncertainty related to Brexit, where British Prime Minister Theresa May postponed the parliamentary vote on her deal with the European Union.Concerns about trade were raised by the release of data showing that exports from China had decelerated, raising concerns that tariff tensions between the U.S. and China would actually impair trade.In addition, uncertainties about interest rate hikes and monetary policy hit cyclical sectors, energy, financials and technology.But markets turned positive as Apple staged a rebound that helped the tech sector as a whole.Fehr said there doesn’t appear to have been a clear catalyst for the shift in the market.“In this environment that we’re in where equities have taken it on the chin over the past several weeks if not months, I think it’s reasonable to see equities rebound in some cases without a specific catalyst but instead on the premise that the concerns or the risks that have been in the spotlight lately aren’t going to stay there forever.”In New York, the Dow Jones industrial average was up 34.31 points at 24,423.26 after being down nearly 480 points and following Friday’s loss of 558.72 points. The S&P 500 index closed up 4.64 points to 2,637.72 after hitting an eight-month low, while the Nasdaq composite was up 51.27 points at 7,020.52.The early market declines prompted some dire forecasts, but Fehr said rumours of the death of the bull market were greatly exaggerated.There are few signs that a recession is going to emerge next year, he said.“But historically the combination of positive GDP growth and positive earnings growth have been more indicative of positive market returns than the end of a bull market.” Toronto stock market dips on weakness in the energy and financials sectors Facebook LinkedIn Twitter Related news Share this article and your comments with peers on social media Keywords Marketwatch TSX gets lift from financials, U.S. markets rise to highest since March North American investors endured another wild ride Monday as markets rebounded from deep declines in trading on broad-based weakness led by the energy sector.“This is a market that just lacks conviction at the moment,” said Craig Fehr, Canadian markets strategist for Edward Jones. last_img read more

Read More →

UK government’s response to Moderna’s publication of efficacy data for its COVID-19 vaccine

first_imgUK government’s response to Moderna’s publication of efficacy data for its COVID-19 vaccine Biotech company Moderna today (Monday 16 November) published positive efficacy results from its Phase 3 studies of its potential COVID-19 vaccine, showing it to be nearly 95% effective in preventing coronavirus.A government spokesperson said:The news from Moderna appears to be good and represents another significant step towards finding an effective COVID19 vaccine. As part of the ongoing work of the Vaccines Taskforce, the government is in advanced discussions with Moderna to ensure UK access to their vaccine as part of the wider UK portfolio.Moderna are currently scaling up their European supply chain which means these doses would become available in spring 2021 in the UK at the earliest.To date, the UK government has secured early access to 350 million vaccines doses through agreements with six separate vaccine developers. This includes 40 million doses of Pfizer/BioNTech’s vaccine, which is based on the same platform as Moderna’s vaccine and if approved by the medicines regulator, is expected to begin delivery as early as December 2020.Read Moderna’s full announcement. /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:coronavirus, covid-19, Europe, european, Government, supply chain, UK, UK Government, vaccine, Vaccineslast_img read more

Read More →